cardioКардиологияKardiologiia0022-90402412-5660Kardiomag10.18087/cardio.2018.11.10194cardio-312Research ArticleОБЗОРЫREVIEWSКлючевые недостатки вторичной профилактики ишемической болезни сердца с помощью лекарственной терапии: роль комбинированных препаратов с постоянными дозами в решении проблемыKey Drawbacks of Secondary Ischemic Heart Disease Prevention With Drug Therapy: the Role of Combination Fixed Dose Preparations in Solution of This ProblemГиляревскийС. Р.GilyarevskyS. R.

Москва

Giliarevskii Sergey R. - PhD, professor.

Moscow

sgilarevsky@rambler.ruГолшмидМ. В.GolshmidM. V.

Москва

Moscow

КузьминаИ. М.KuzminaI. M.

Moscow

ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииРоссияMedical Academy of Continuing EducationRussian FederationГБУЗ «НИИ скорой помощи им. Н.В. Склифосовского» Департамента здравоохранения г. МосквыРоссияN.V. Sklifosovsky Research Institute for Critical CareRussian Federation20182411201858111723Copyright © Kardiomag, 20182018KardiomagKardiomaghttps://cardio.elpub.ru/jour/about/submissions#copyrightNoticehttps://cardio.elpub.ru/jour/article/view/312

В статье рассматривается проблема низкой приверженности больных ишемической болезнью сердца (ИБС) к применению медикаментозной терапии, соответствующей действующим рекомендациям, в том числе у больных, которым были выполнены инвазивные вмешательства, направленные на реваскуляризацию миокарда. На основании анализа литературы предпринята попытка ответить на вопрос, какие из компонентов такой терапии реже всего продолжают принимать больные ИБС. Обсуждаются подходы к поиску оптимального состава комбинированного препарата, содержащего постоянные дозы в-адреноблокатора и ингибитора ангиотензинпревращающего фермента. Приводятся данные о роли в лечении больных ИБС бисопролола и периндоприла, которые включены в новый комбинированный препарат престилол.

In this article we deal with the problem of low adherence of patients with ischemic heart disease (IHD) to drug therapy congruent to current recommendations including patients who underwent invasive interventions aimed at myocardial revascularization. Based on analysis of literature, we undertake an attempt to answer the question: which of components of this therapy patients with IHD are the least likely to continue taking? We also discuss approaches to the search for optimal composition of a combination preparation with fixed doses of an adreno-blocker and angiotensin converting enzyme inhibitor. Based on analysis of literature we undertook an attempt to answer a question: which of components of this therapy patients with IHD are least likely to continue taking. We also included in this article discussion of approaches to the search of optimal composition of a combination preparation containing fixed doses of a в-adrenoblocker and angiotensin converting enzyme inhibitor, as well as data on the role in the treatment of patients with IHD of bisoprolol and perindopril. Fixed doses of these agents have been included into a novel combination preparation.

ишемическая болезнь сердцапрофилактикаприверженность к терапиикомбинированные препаратыischemic heart diseasepreventiontherapy adherencecombination drugsReferencesPinho-Gomes A. C., Azevedo L., Ahn J. M. et al. Compliance With Guideline-Directed Medical Therapy in Contemporary Coronary Revascularization Trials. J Am Coll Cardiol 2018;71:591-602.Pinho-Gomes A. C., Azevedo L., Ahn J. M. et al. Compliance With Guideline-Directed Medical Therapy in Contemporary Coronary Revascularization Trials. J Am Coll Cardiol 2018;71:591-602.Okrainec K., Platt R., Pilote L., Eisenberg M.J. Cardiac medical therapy in patients after undergoing coronary artery bypass graft surgery: a review of randomized controlled trials. J Am Coll Cardiol 2005;45:177-184.Okrainec K., Platt R., Pilote L., Eisenberg M.J. Cardiac medical therapy in patients after undergoing coronary artery bypass graft surgery: a review of randomized controlled trials. J Am Coll Cardiol 2005;45:177-184.Bradshaw P.J., Jamrozik K., Gilfillan I., Thompson P. L. Preventing recurrent events long term after coronary artery bypass graft: suboptimal use of medications in a population study. Am Heart J 2004;147:1047-1053Bradshaw P.J., Jamrozik K., Gilfillan I., Thompson P. L. Preventing recurrent events long term after coronary artery bypass graft: suboptimal use of medications in a population study. Am Heart J 2004;147:1047-1053Goyal A., Alexander J. H., Hafley G. E. et al. Outcomes associated with the use of secondary prevention medications after coronary artery bypass graft surgery. Ann Thorac Surg 2007;83:993-1001.Goyal A., Alexander J. H., Hafley G. E. et al. Outcomes associated with the use of secondary prevention medications after coronary artery bypass graft surgery. Ann Thorac Surg 2007;83:993-1001.Iqbal J., Zhang Y. J., Holmes D. R. et al. Optimal medical therapy improves clinical outcomes in patients undergoing revascularization with percutaneous coronary intervention or coronary artery bypass grafting: insights from the Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery (SYNTAX) trial at the 5-year follow-up. Circulation 2015;131:1269-1277.Iqbal J., Zhang Y. J., Holmes D. R. et al. Optimal medical therapy improves clinical outcomes in patients undergoing revascularization with percutaneous coronary intervention or coronary artery bypass grafting: insights from the Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery (SYNTAX) trial at the 5-year follow-up. Circulation 2015;131:1269-1277.Al-Lamee R., Thompson D., Dehbi H. M. et al. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial. Lancet 2018;391:31-40.Al-Lamee R., Thompson D., Dehbi H. M. et al. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial. Lancet 2018;391:31-40.Iqbal J., Serruys P. W. Optimal medical therapy is vital for patients with coronary artery disease and acute coronary syndromes regardless of revascularization strategy. Ann Transl Med 2017;5:14-0.Iqbal J., Serruys P. W. Optimal medical therapy is vital for patients with coronary artery disease and acute coronary syndromes regardless of revascularization strategy. Ann Transl Med 2017;5:14-0.Bansilal S., Castellano J. M., Fuster V. Global burden of CVD: focus on secondary prevention of cardiovascular disease. Int J Cardiol 2015;201 Suppl 1: S1-7. DOI: 10.1016/S0167-5273(15)31026-3.Bansilal S., Castellano J. M., Fuster V. Global burden of CVD: focus on secondary prevention of cardiovascular disease. Int J Cardiol 2015;201 Suppl 1: S1-7. DOI: 10.1016/S0167-5273(15)31026-3.Librero J., Sanfelix-Gimeno G., Peiro S. Medication Adherence Patterns after Hospitalization for Coronary Heart Disease. A Population-Based Study Using Electronic Records and Group-Based Trajectory Models. PLoS One. 201623;11 (8):e0161381. DOI: 10.1371/journal.pone.0161381.Librero J., Sanfelix-Gimeno G., Peiro S. Medication Adherence Patterns after Hospitalization for Coronary Heart Disease. A Population-Based Study Using Electronic Records and Group-Based Trajectory Models. PLoS One. 201623;11 (8):e0161381. DOI: 10.1371/journal.pone.0161381.Yusuf S., Islam S., Chow C. K. et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet 2011;378:1231-1243.Yusuf S., Islam S., Chow C. K. et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet 2011;378:1231-1243.Thom S., Poulter N., FieldJ. et al. Effects ofa Fixed-Dose Combination Strategy on Adherence and Risk Factors in Patients With or at High Risk of CVD: The UMPIRE Randomized Clinical Trial. JAMA 2013;310 (9):918-929. DOI:10.1001/jama.2013.277064Thom S., Poulter N., FieldJ. et al. Effects ofa Fixed-Dose Combination Strategy on Adherence and Risk Factors in Patients With or at High Risk of CVD: The UMPIRE Randomized Clinical Trial. JAMA 2013;310 (9):918-929. DOI:10.1001/jama.2013.277064Castellano J. M., Sanz G., Fernandez Ortiz A. et al. A polypill strategy to improve global secondary cardiovascular prevention: from concept to reality. J Am Coll Cardiol 2014;64:613-621. DOI: 10.1016/j.jacc.2014.06.009.Castellano J. M., Sanz G., Fernandez Ortiz A. et al. A polypill strategy to improve global secondary cardiovascular prevention: from concept to reality. J Am Coll Cardiol 2014;64:613-621. DOI: 10.1016/j.jacc.2014.06.009.The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13.The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13.Vanoli E., Dei Cas L., Willenheimer R. Sudden death prevention in heart failure: The case of CIBIS III. Heart Int 2006;2:73. DOI: 10.4081/hi.2006.73.Vanoli E., Dei Cas L., Willenheimer R. Sudden death prevention in heart failure: The case of CIBIS III. Heart Int 2006;2:73. DOI: 10.4081/hi.2006.73.Dungen H. D., Apostolovic S., Inkrot S. et al. Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS- ELD trial. Eur J Heart Fail 2011;13:670-680.Dungen H. D., Apostolovic S., Inkrot S. et al. Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS- ELD trial. Eur J Heart Fail 2011;13:670-680.Krum H., Hill J., Fruhwald F. et al. Tolerability of beta-blockers in elderly patients with chronic heart failure: the COLA II study. Eur J Heart Fail 2006;8:302-307.Krum H., Hill J., Fruhwald F. et al. Tolerability of beta-blockers in elderly patients with chronic heart failure: the COLA II study. Eur J Heart Fail 2006;8:302-307.Edelmann F., Musial-Bright L., Gelbrich G. et al. Tolerability and Feasibility of Beta-Blocker Titration in HFpEF Versus HFrEF: nsights From the CIBIS-ELD Trial. JACC Heart Fail 2016;4:140-149. DOI: 10.1016/j.jchf.2015.10.008.Edelmann F., Musial-Bright L., Gelbrich G. et al. Tolerability and Feasibility of Beta-Blocker Titration in HFpEF Versus HFrEF: nsights From the CIBIS-ELD Trial. JACC Heart Fail 2016;4:140-149. DOI: 10.1016/j.jchf.2015.10.008.Fonarow G. C. Managing the patient with diabetes mellitus and heart failure: issues and considerations. Am J Med 2004; 116 (Suppl. 5A): 76S-88S.Fonarow G. C. Managing the patient with diabetes mellitus and heart failure: issues and considerations. Am J Med 2004; 116 (Suppl. 5A): 76S-88S.Erdmann E. Safety and tolerability of beta-blockers: prejudices and reality. Eur Heart J Suppl 2009;11 Suppl A: A21-25.Erdmann E. Safety and tolerability of beta-blockers: prejudices and reality. Eur Heart J Suppl 2009;11 Suppl A: A21-25.Yang T., Jiang Y., Hao Y. Comparison of bisoprolol to a metopro-lol CR/ZOK tablet for control of heart rate and blood pressure in mild-to-moderate hypertensive patients: the CREATIVE study. Hypertens Res 2017;40:79-86. DOI: 10.1038/hr.2016.101. Epub 2016 Aug 18.Yang T., Jiang Y., Hao Y. Comparison of bisoprolol to a metopro-lol CR/ZOK tablet for control of heart rate and blood pressure in mild-to-moderate hypertensive patients: the CREATIVE study. Hypertens Res 2017;40:79-86. DOI: 10.1038/hr.2016.101. Epub 2016 Aug 18.The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery Disease Investigators. Efficacy of perin-dopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-788.The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery Disease Investigators. Efficacy of perin-dopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-788.Beckett N. S., Peters R., Fletcher A. E. et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008;358:1887-1898.Beckett N. S., Peters R., Fletcher A. E. et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008;358:1887-1898.Dahlof B., Sever P. S., Poulter N. R. et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflume-thiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906.Dahlof B., Sever P. S., Poulter N. R. et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflume-thiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906.ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007;370:829-840.ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007;370:829-840.Ceconi C., Fox K. M., Remme W.J. et al. ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc Res 200;73:237-246.Ceconi C., Fox K. M., Remme W.J. et al. ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc Res 200;73:237-246.

The authors declare that there are no conflicts of interest present.